ACHN Xenograft Model Overview

The ACHN xenograft model is derived from a human renal cell carcinoma (RCC) cell line, ACHN, established from a primary tumor of the kidney. Renal cell carcinoma is one of the most common and aggressive forms of kidney cancer, with a high incidence of metastasis and resistance to conventional therapies. The ACHN xenograft model is a widely used preclinical tool for studying the biology of RCC, particularly clear cell renal carcinoma, and for evaluating novel therapeutic strategies aimed at improving the prognosis of patients with RCC. Given its ability to replicate key features of RCC, including angiogenesis, tumor progression, and metastasis, the ACHN xenograft model is critical for testing targeted therapies, immunotherapies, and combination treatment regimens for advanced kidney cancer.

Request a Custom Quote for ACHN Xenograft Model

Biological and Molecular Characteristics

ACHN cells are characterized by their epithelial origin and express various markers associated with renal cell carcinoma, such as cytokeratins, epithelial membrane antigen (EMA), and the vimentin marker. The model is particularly relevant for studying clear cell renal carcinoma (ccRCC), which is the most common subtype of RCC, as it harbors mutations in the VHL (von Hippel-Lindau) gene. The loss of VHL function leads to the upregulation of hypoxia-inducible factors (HIFs), particularly HIF-1α and HIF-2α, which drive the expression of genes involved in angiogenesis, cell survival, and metastasis. Additionally, ACHN cells exhibit activation of key signaling pathways such as PI3K/AKT and MAPK/ERK, which are implicated in tumor cell survival, proliferation, and invasion. These molecular features make the ACHN xenograft model particularly valuable for studying RCC biology and for testing novel therapies targeting these pathways.

Marker	Expression Level	Function
Cytokeratin	High	Epithelial cell marker
EMA	High	Epithelial membrane antigen
Vimentin	Elevated	Intermediate filament involved in cell structure
VHL	Mutated	Tumor suppressor gene regulating hypoxia response
HIF-1α/HIF-2α	Elevated	Transcription factors involved in angiogenesis

In Vivo Model Development and Tumorigenicity

The ACHN xenograft model is typically established by subcutaneously implanting ACHN cells into immunocompromised mice, such as NOD/SCID or NSG mice, which lack functional T and B cells. Upon implantation, the cells form solid tumors that replicate the histopathological features of human RCC, including high cellularity, necrosis, and significant vascularization. The tumors also demonstrate angiogenesis, a hallmark of RCC, due to the dysregulated expression of HIF-1α and HIF-2α. The ACHN xenograft model is particularly useful for studying tumor growth, metastasis, and evaluating therapies that target tumor vasculature, as RCC tumors are highly vascularized.

In addition to subcutaneous implantation, orthotopic implantation of ACHN cells into the kidney of immunocompromised mice can be performed to more accurately replicate the natural site of tumor growth. This orthotopic model is more clinically relevant as it allows for the study of tumor growth, local invasion, and metastasis, including peritoneal dissemination and distant spread to the lungs and bones. The ACHN orthotopic model is especially useful for testing therapies aimed at targeting both the primary tumor and metastases in RCC.

Request a Custom Quote for ACHN Xenograft Model

Histopathology and Immunohistochemical Profile

Histopathological examination of ACHN xenografts reveals the characteristic features of renal cell carcinoma, including the presence of irregular glandular structures and areas of necrosis. Immunohistochemical staining of ACHN xenografts shows strong expression of epithelial markers such as cytokeratin and EMA, confirming the epithelial origin of the tumor. Additionally, the tumors exhibit elevated levels of vimentin, a marker of mesenchymal transition, which is commonly seen in metastatic RCC. Elevated expression of HIF-1α and HIF-2α is observed in ACHN xenografts, reflecting the upregulation of these transcription factors due to VHL mutation. The tumors also show high levels of phosphorylated AKT, indicating the activation of the PI3K/AKT signaling pathway, which promotes cell survival and proliferation. CD31 staining reveals significant tumor vascularization, which is essential for the rapid growth of RCC tumors.

Preclinical Applications and Drug Response

The ACHN xenograft model is extensively used to evaluate the efficacy of various therapeutic agents for renal cell carcinoma. Given the model’s sensitivity to angiogenesis inhibitors, it is particularly valuable for testing drugs that target the tumor vasculature, such as VEGF inhibitors. The ACHN xenograft model is also widely used to assess the effects of chemotherapy agents, such as sunitinib and sorafenib, which are commonly used to treat RCC. These agents target key signaling pathways involved in tumor growth and angiogenesis, such as VEGF and PDGF receptors.

Additionally, the ACHN xenograft model is highly relevant for studying targeted therapies aimed at the VHL/HIF pathway. Given the loss of VHL function in these cells, the model is used to evaluate novel agents that inhibit HIF-1α and HIF-2α or restore VHL function to prevent tumor progression. The ACHN model is also increasingly used to test immunotherapies, including immune checkpoint inhibitors, which are being explored in RCC treatment. The model’s ability to replicate key features of human RCC, including its angiogenesis, metastasis, and resistance to therapy, makes it an ideal platform for evaluating the efficacy of novel immunotherapies, combination therapies, and drugs targeting RCC-specific signaling pathways.

Request This Model

To request the ACHN xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for ACHN Xenograft Model